• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by IM Cannabis Corp.

    2/21/23 10:56:41 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $IMCC alert in real time by email
    SC 13G 1 doc1.htm NONE Schedule 13G


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. n/a )*
     
    IM CANNABIS CORP. 

    (Name of Issuer)
     
    Common Shares, no par value

    (Title of Class of Securities)
     
    44969Q307

    (CUSIP Number)
     
    January 20, 2023

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         o  Rule 13d-1(b)
     
         x  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  44969Q307      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     Luminera Derm Ltd.
    00-0000000
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   o
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Israel
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     1,514,344
       
    6 SHARED VOTING POWER
      
     0
       
    7 SOLE DISPOSITIVE POWER
      
     1,514,344
       
    8 SHARED DISPOSITIVE POWER
      
     0
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     1,514,344*
    *Represents units held by reporting person consisting of 757,172 common shares, no par value ("Shares"), and warrants exercisable for an additional 757,172 Shares.
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     14.09%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     CO
     

    FOOTNOTES
      
     Based on 9,988,849 outstanding shares of the Issuer as of January 20, 2023, plus 757,172 Shares in in underlying warrants beneficially owned by the reporting person and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    IM CANNABIS CORP.

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    Kibbutz Glil Yam
    Central District
    Israel 4690500

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    Luminera Derm Ltd.

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    1 Bat Sheba Lod
    Lod
    Israel 7116001

     
    (c)
    Citizenship
     
     
    Israel

     
    (d)
    Title of Class of Securities
     
     
    Common Shares, no par value

     
    (e)
    CUSIP Number
     
     
    44969Q307

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    o
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 1,514,344

     
    (b)
    Percent of class: 14.09%

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 1,514,344

     
    (ii)
    Shared power to vote or to direct the vote: 0

     
    (iii)
    Sole power to dispose or to direct the disposition of: 1,514,344

     
    (iv)
    Shared power to dispose or to direct the disposition of: 0

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
    N/A
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    N/A
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    N/A
     
    Item 8.
    Identification and Classification of Members of the Group
     
    N/A
     
    Item 9.
    Notice of Dissolution of Group
     
    N/A
     
     
     

     
     
     
    Item 10.
    Certification
      
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     Luminera Derm Ltd.
     
        
    Date: February 19, 2023
    By:
    /s/  David Dadi Segal 
       Name: David Dadi Segal 
       Title:  Chairman 
        
     
    Footnotes:

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $IMCC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMCC

    DatePrice TargetRatingAnalyst
    10/5/2021$8.00Buy
    ROTH Capital
    7/14/2021Buy
    Desjardins
    7/14/2021$10.50Buy
    Desjardins
    More analyst ratings

    $IMCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH Capital initiated coverage on IM Cannabis with a new price target

    ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00

    10/5/21 7:57:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IMC Mortgage Co

    Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy

    7/14/21 8:40:32 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IM Cannabis with a new price target

    Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50

    7/14/21 7:01:53 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    SEC Filings

    View All

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    8/13/25 5:03:53 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form F-3 filed by IM Cannabis Corp.

    F-3 - IM Cannabis Corp. (0001792030) (Filer)

    8/13/25 4:02:13 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    8/12/25 8:15:25 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Financials

    Live finance-specific insights

    View All

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Second Quarter 2025 Financial Results

    IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights   14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M  306% Gross profit increase vs.

    8/12/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET

    TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.   About IM Cannabis Corp. IMC (NASDAQ:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company lever

    8/4/25 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IM Cannabis Corp.

    SC 13G - IM Cannabis Corp. (0001792030) (Subject)

    2/21/23 10:56:41 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by IM Cannabis Corp. (Amendment)

    SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)

    2/8/23 1:29:15 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

    SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)

    2/2/23 10:38:01 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Second Quarter 2025 Financial Results

    IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights   14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M  306% Gross profit increase vs.

    8/12/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET

    TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.   About IM Cannabis Corp. IMC (NASDAQ:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company lever

    8/4/25 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Leadership Updates

    Live Leadership Updates

    View All

    IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

    TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

    9/11/24 8:30:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer

    TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023.  This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin

    10/10/23 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary

    Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 13, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of Rinat Efrima as the new Chief Executive Officer of IMC Holdings Ltd. ("IMC Holdings"), the Company's wholly-owned Israeli subsidiary. Ms. Efrima will join the Company in the first quarter of 2022. In addition, Ya

    1/13/22 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care